Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIUMVI vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
Terminal elimination half-life is approximately 19-20 days (range 11-30 days) in patients with relapsing multiple sclerosis. The long half-life supports every-6-month dosing.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Ublituximab is a monoclonal antibody catabolized into small peptides and amino acids via general protein degradation pathways; no specific metabolic enzymes are involved.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
BRIUMVI (ublituximab) is a monoclonal antibody. Elimination occurs via intracellular catabolism and is not excreted renally or fecally in significant amounts. No specific excretion data available.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Not extensively bound to plasma proteins (expected low binding for monoclonal antibodies); specific % not reported.
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
Approximately 3.5 L (not weight-based; ~0.05 L/kg for a 70 kg patient). Small Vd consistent with limited extravascular distribution of monoclonal antibodies.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
100% (intravenous administration only; not administered via other routes).
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No dose adjustment is recommended for patients with mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min) or end-stage renal disease.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Safety and effectiveness in pediatric patients (age <18 years) have not been established. No recommended dosing.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment is recommended. Clinical studies did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
None
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Infusion reactions (may require premedication and monitoring),Increased risk of infections (including serious and life-threatening infections),Progressive multifocal leukoencephalopathy (PML) in patients treated with anti-CD20 therapies,Hepatitis B reactivation (perform HBV screening before initiation),Immunoglobulin levels reduction requiring monitoring,Increased risk of malignancies (breast cancer observed in clinical trials)
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
Active hepatitis B infection,Severe, active infections (until resolved)
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
No known food interactions. Grapefruit and other CYP450 modulators are not expected to affect ublituximab as it is a monoclonal antibody cleared via catabolism.
No known food interactions. Take with or without food.
BRIUMVI (ublituximab) is a monoclonal antibody, and Ig G antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimester. Based on its mechanism of action (CD20-mediated B-cell depletion), there is a potential risk of transient peripheral B-cell depletion in the fetus. Animal studies have not been conducted with ublituximab; however, other anti-CD20 antibodies have shown no teratogenicity but can cause neonatal B-cell depletion. The drug should be avoided during pregnancy unless the benefit justifies the potential risk.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
It is unknown whether ublituximab is excreted in human milk. Monoclonal antibodies are generally present in breast milk in low amounts, but absorption by the infant is limited due to gastrointestinal degradation. Since ublituximab can cause B-cell depletion, a risk to the breastfed infant cannot be excluded. The M/P ratio is not known.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No specific dose adjustments are recommended during pregnancy due to lack of pharmacokinetic data. However, pregnancy can alter clearance and volume of distribution for monoclonal antibodies, potentially affecting exposure. Current guidelines do not specify dose modifications for ublituximab in pregnancy; clinical judgment is advised.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
Premedicate with corticosteroids, antihistamines, and acetaminophen to reduce infusion reactions. Monitor for hypersensitivity reactions, especially during first infusion. Screen for hepatitis B and tuberculosis before initiation. Avoid live vaccines during treatment. Consider JCV antibody status due to risk of progressive multifocal leukoencephalopathy (PML) with anti-CD20 therapies.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
You must take premedications before each infusion to lower the risk of allergic reactions.,Report any symptoms like fever, chills, rash, or difficulty breathing during or after infusion.,Inform your doctor if you have a history of hepatitis B, tuberculosis, or any infections.,Do not receive live vaccines while on this medication and for a period after stopping.,This drug may increase your risk of infections; contact your doctor if you develop signs of infection.,You will need regular blood tests to monitor for side effects.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIUMVI vs ARZERRA, answered by our medical review team.
BRIUMVI is a Monoclonal Antibody that works by BRIUMVI (ublituximab) is a recombinant, chimeric, humanized monoclonal antibody that binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding to CD20 results in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to B-cell depletion.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIUMVI and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIUMVI is: BRIUMVI (ublituximab) 150 mg administered as an intravenous infusion over 4 hours once weekly for 3 weeks, then 150 mg once every 6 months thereafter.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIUMVI and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIUMVI is classified as Category C. BRIUMVI (ublituximab) is a monoclonal antibody, and IgG antibodies are known to cross the placenta increasingly after the first trimester, with highest transfer in the third trimes. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.